Jesse
Established Member
Seems like the results are not ordered chronologically. For me it's the third result.BTW, if I type 'Jonathan Edwards' into the Qeios search box, I don't get this latest paper - just some older ones. Is that just me?
Seems like the results are not ordered chronologically. For me it's the third result.BTW, if I type 'Jonathan Edwards' into the Qeios search box, I don't get this latest paper - just some older ones. Is that just me?
Yes, but I envisage the T cell macrophage interaction as occurring within a highly controlled microenvironment within lymph node or spleen, where bacterial products are not expected to be present at levels that would generate inflammation.
The advantage of gamma interferon is that T cells can traffic around and secrete it all over the place.
The primary issue I see is in the lack of specificity of an interferon gamma-mediated mechanism. Purely theoretically, IFN-g could “prime” a macrophage to be more reactive to FcgRI binding, but the level of interferon gamma stimulation required for this priming would almost certainly also make them more reactive to LPS and PAMPs (bacterial crud, for anyone unfamiliar), oxidized cell free DNA…pretty much anything that activates a TLR or a cytosolic sensor. IFN-g is well known as a pretty broad spectrum sensitizer in that regard.
Interferon gamma would potentiate any circulating myeloid if it had to get in the circulation to cause symptoms.
The potentiation doesn’t occur through direct interaction with a T cell, just stimulation of the IFNGRI don't follow that. A T cell is not going to interact with a myeloid cells in the bloodstream. They will be going past each other like F1 drivers.
The potentiation doesn’t occur through direct interaction with a T cell, just stimulation of the IFNGR
Except that other examples of hypothalmic signaling require a sufficient circulatory concentration. You can induce fever by exogenous IL-1. That indicates that the hypothalmus detects a critical concentration of the cytokine, not specific cells. Similarly, I recall a study posted by someone on another thread showing that injection of a cocktail of cytokines induces myalgia. [Edit: viral infection features detectable levels of type I interferon in the blood]But the receptor isn't going to be stimulated by a T cell going past like Schumacher in a sea of plasma and red cells. I don't know the details of concentrations but my guess is that gamma interferon signalling in a tissue microenvironment is going to be several orders of magnitude more efficient than puffing some out in the breeze and hoping another cell gets a whiff. And any two white cells in blood probably do not get even enough for a whiff for more than fractions of a second.
Except that other examples of hypothalmic signaling require a sufficient circulatory concentration. You can induce fever by exogenous IL-1. That indicates that the hypothalmus detects a critical concentration of the cytokine, not specific cells. Similarly, I recall a study posted by someone on another thread showing that injection of a cocktail of cytokines induces myalgia. [Edit: viral infection features detectable levels of type I interferon in the blood]
I've seen some very tentative evidence that e.g. circulatory myeloids make it to the hypothalamus and secrete cytokines locally to induce responses. But when that occurs, it would've been at a sufficient concentration to also observe in the circulation. The idea that a small concentration of IFN-g spewing T-cells would be enough to zip to the hypothalamus and trigger the intensity of symptoms in ME/CFS seems at odds with every other similar example in the literature.
Can anyone provide me with a link to this poll, please? I wasn't able to find it on a search.I don't know whether they assessed time delay to onset of fatigue. My information on this comes partly from asking individuals but mostly from the poll I did here. You do not need a very big poll to see that time delays before fatigue onset are common and very variable - some people say six months.
Qeios paper said:Targeting T cell populations, particularly those expected to provide protection from viral infection, has been met with little enthusiasm in the context of other T cell-mediated conditions. Long-term T cell depletion with anti-CD52 proved to be associated with relatively little morbidity in trials for rheumatoid disease, but a more subtle approach targeting T cell signalling probably remains a more attractive option, perhaps through the JAK/STAT pathway.
- more subtle approach T cell signalling JAK/STAT pathway = JAK-STAT inhibitors
Can anyone speak to the horribility or otherwise of JAK-STAT inhibitors?
As a side-question, why do these drugs all seem to need to be infused/injected? Google isn't very helpful on this. Presumably they'd all get wrecked by stomach acid but what is it about them, as opposed to, say, aspirin, that makes them wreckable?
Can anyone speak to the horribility or otherwise of JAK-STAT inhibitors?
The main concern is still the same, though. Why would we expect this gamma-interferon spewing T cells to only have salient effect at the hypothalamus, or at certain peripheral nerves (and potentially interacting with macrophages in muscle as mentioned in the text), but not anywhere else we would expect circulating T cells to interact with and sensitize other cells? This wouldn’t only be in the circulation, but also gut and skin as previously mentioned and probably other locations I’m not thinking of.If cells get to hypothalamus and signal I see no need for that to be reflected in circulation.
a few minor editing suggestions:
Why would we expect this gamma-interferon spewing T cells to only have salient effect at the hypothalamus, or at certain peripheral nerves (and potentially interacting with macrophages in muscle as mentioned in the text), but not anywhere else we would expect circulating T cells to interact with and sensitize other cells?
I am sorry that you are confused @Simon M. I think at some point there must have been crossed wires.
One thing maybe worth adding is that the neural mechanisms that generate pain can also directly generate weakness, even without pain. There is a complete block to voluntary use of a muscle group but electrical stimulation of the muscle will produce a response.
I think a plausible model for ME/CFS is one where both nerves and immune cells are involved in generating inappropriate signals in the absence of any pathology in muscle itself. What I am less clear about is whether the neural signals actually loop back on to the immune cell function. They may do but I don't yet see a very convincing story for that. But either way all this signalling is a bit like the complex electronics of a Mercedes Benz that you would like to drive up the road. It doesn't go because of some too clever feedback safety programme that is completely invisible to the driver. There is nothing wrong with the engine but the engine sends signals to the software system in the electronic drive control which sends signals back to the engine to stop. CBT for the drive is not going to help!!
I am confused in (I think) a similar way to @Simon M here. If I'm understanding correctly, you're saying in your paper that some signalling is going on that's telling a PwME that they're exhausted, even when the mitochrondria are fully charged, etc. etc. I don't understand why we then can't push through without ill effect. Even if there's some sort of feedback loop that makes the symptom of exhaustion worse and worse, why can't we push through the worse exhaustion?The false argument is that false or exaggerated signals can be overcome by pushing through. You cannot do that for lupus or RA. It might seem you should be able to for ME/CFS but if there is a loop that amplifies the immune signal further every time you push then you cannot.
The false argument depends on this naive distinction between mind and body (Cartesian dualism) that the biopsychosocial people make, with the mind being some 'other' causal unit. My work on brain biophysics tells me that this is nonsense. The 'psyche' of psychology is a bogus concept. It is entirely unreasonable to suggest that there is a 'me' that can override the casual pathways in my body.
Jonathan Edwards said:One thing maybe worth adding is that the neural mechanisms that generate pain can also directly generate weakness, even without pain. There is a complete block to voluntary use of a muscle group but electrical stimulation of the muscle will produce a response.
Jonathan Edwards said:On a broader front, it may be legitimate to see all these chronic disease states – autoimmunity, autoinflammatory states, familial fever syndromes, and ME/CFS – as each feeding off built-in risks associated with positive feedback (as in B cell clonal expansion), autocatalytic (as in coagulation and complement cascades), or ‘focussing’ (as in leucocyte chemotaxis) mechanisms that can get out of control but are still ultimately sensitive to some overriding homeostatic controls.
Ah but there’s a little detail about exacerbated localized type I interferon production [edit: preceding T cell infiltration] that is a good candidate for explaining that location specificity of T cell activationThe cells that give us psoriasis only give trouble in skin and entheses pretty much.
Does this blocking of voluntary use of a muscle group happen to people in normal health?
You've argued against this possibility by saying that none of us have a 'me' that can override the causal pathways of the body but I surely have a 'me' that can decide whether to try to raise my arm or not.